Cargando…

Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.

BACKGROUND: Isoferulic acid (IFA) is a main active ingredient of the rhizoma of Cimicifuga beracleifolia, which is used frequently in Japanese traditional medicine as an anti-inflammatory drug. It has been revealed that IFA inhibits the production of macrophage inflammatory protein-2 (MIP-2), which...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, S, Ochiai, H, Mantani, N, Kogure, T, Shibahara, N, Terasawa, K
Formato: Texto
Lenguaje:English
Publicado: 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781695/
https://www.ncbi.nlm.nih.gov/pubmed/11405556
_version_ 1782131943844872192
author Sakai, S
Ochiai, H
Mantani, N
Kogure, T
Shibahara, N
Terasawa, K
author_facet Sakai, S
Ochiai, H
Mantani, N
Kogure, T
Shibahara, N
Terasawa, K
author_sort Sakai, S
collection PubMed
description BACKGROUND: Isoferulic acid (IFA) is a main active ingredient of the rhizoma of Cimicifuga beracleifolia, which is used frequently in Japanese traditional medicine as an anti-inflammatory drug. It has been revealed that IFA inhibits the production of macrophage inflammatory protein-2 (MIP-2), which is a murine counterpart of the chemokine family that may contribute to the pathogenesis of inflammatory diseases through the chemotactic activity for inflammatory and immune effector cells. AIM OF THE STUDY: In this study, we investigated the therapeutic effect of IFA on the progression of lethal influenza virus pneumonia in mice by comparison with that of dexamethasone (DX), a potent inhibitor for various inflammatory cytokines including MIP-2. METHODS: Mice were infected by intranasal inoculation of influenza virus under ether anesthesia. The IFA or DX was given by oral administration once daily for 4 days after infection. After infection, the survival rate and the change in body weight were daily monitored. RESULTS: IFA administration markedly improved the survival rate and body weight loss of influenza virus-infected mice in a suitable dose range (0.5 mg/day). However, DX administration did not show a beneficial effect at any dose. CONCLUSION: These data suggested that IFA is a novel tool not only for the intervention therapy, but also for the studies on the pathogenesis of influenza virus-induced pneumonia.
format Text
id pubmed-1781695
institution National Center for Biotechnology Information
language English
publishDate 2001
record_format MEDLINE/PubMed
spelling pubmed-17816952007-01-25 Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. Sakai, S Ochiai, H Mantani, N Kogure, T Shibahara, N Terasawa, K Mediators Inflamm Research Article BACKGROUND: Isoferulic acid (IFA) is a main active ingredient of the rhizoma of Cimicifuga beracleifolia, which is used frequently in Japanese traditional medicine as an anti-inflammatory drug. It has been revealed that IFA inhibits the production of macrophage inflammatory protein-2 (MIP-2), which is a murine counterpart of the chemokine family that may contribute to the pathogenesis of inflammatory diseases through the chemotactic activity for inflammatory and immune effector cells. AIM OF THE STUDY: In this study, we investigated the therapeutic effect of IFA on the progression of lethal influenza virus pneumonia in mice by comparison with that of dexamethasone (DX), a potent inhibitor for various inflammatory cytokines including MIP-2. METHODS: Mice were infected by intranasal inoculation of influenza virus under ether anesthesia. The IFA or DX was given by oral administration once daily for 4 days after infection. After infection, the survival rate and the change in body weight were daily monitored. RESULTS: IFA administration markedly improved the survival rate and body weight loss of influenza virus-infected mice in a suitable dose range (0.5 mg/day). However, DX administration did not show a beneficial effect at any dose. CONCLUSION: These data suggested that IFA is a novel tool not only for the intervention therapy, but also for the studies on the pathogenesis of influenza virus-induced pneumonia. 2001-04 /pmc/articles/PMC1781695/ /pubmed/11405556 Text en
spellingShingle Research Article
Sakai, S
Ochiai, H
Mantani, N
Kogure, T
Shibahara, N
Terasawa, K
Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
title Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
title_full Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
title_fullStr Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
title_full_unstemmed Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
title_short Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
title_sort administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781695/
https://www.ncbi.nlm.nih.gov/pubmed/11405556
work_keys_str_mv AT sakais administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice
AT ochiaih administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice
AT mantanin administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice
AT koguret administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice
AT shibaharan administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice
AT terasawak administrationofisoferulicacidimprovedthesurvivalrateoflethalinfluenzaviruspneumoniainmice